NCT00742872

Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

A Prospective Double-Blind Placebo-Controlled Trial of Mosapride in Patients With Constipation-Predominant Irritable Bowel Syndrome

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: American University of Beirut Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Mosapride, an agent which acts on serotonin receptors in the gastrointestinal tract, is effective in the treatment of constipation-predominant irritable bowel syndrome (C-IBS).

Conditions

• Constipation-Predominant Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Mosapride Citrate	One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
DRUG	Placebo	One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.

Timeline

• Start date: 2008-09-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2008-08-28
• Last updated: 2013-04-09
• Results posted: 2013-04-09

Locations

1 site across 1 country: Lebanon